3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia

Acute Management of Severe-Range Hypertension

A hypertensive emergency in pregnancy is defined as acute-onset, severe-range blood pressure (systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg) that is sustained for 15 minutes or longer. Severe-range blood pressure is an obstetric emergency that drastically elevates maternal risk for hemorrhagic stroke, hypertensive encephalopathy, cardiopulmonary decompensation, and placental abruption.

Treatment Goals and Clinical Timing

• Goal: Lower systolic BP to 140–150 mmHg and diastolic BP to 90–100 mmHg within 30 to 60 minutes of confirmation.
• Precaution: Avoid precipitous drops in blood pressure (e.g., diastolic BP <80 mmHg), which can cause maternal cerebral hypoperfusion and impair uteroplacental blood flow, resulting in non-reassuring fetal heart rate tracings.

First-Line Pharmacologic Algorithms

                    [ Severe-Range BP Detected: SBP ≥160 or DBP ≥110 mmHg ]
                                        │
                       Confirm persistence within 15 minutes
                                        │
         ┌──────────────────────────────┼──────────────────────────────┐
         ▼                              ▼                              ▼
  [ IV Labetalol ]              [ IV Hydralazine ]         [ Oral IR Nifedipine ]
20 mg IV over 2 min           5–10 mg IV over 2 min        10–20 mg PO (swallow)
         │                              │                              │
Recheck BP at 10 min           Recheck BP at 20 min         Recheck BP at 20 min
         │                              │                              │
If still severe:               If still severe:             If still severe:
40 mg IV over 2 min           10 mg IV over 2 min          20 mg PO
         │                              │                              │
Recheck BP at 10 min           Recheck BP at 20 min         Recheck BP at 20 min
         │                              │                              │
If still severe:               If still severe:             If still severe:
80 mg IV over 2 min           Switch to Labetalol          20 mg PO (max 50 mg)
(Max single dose 80 mg;       or Nifedipine                (Switch to IV line)
 cumulative max 220–300 mg)   (Max dose 20–30 mg)          

1. Intravenous Labetalol

• Mechanism: Combined non-selective beta-blocker and selective alpha-1 adrenergic blocker, decreasing systemic vascular resistance without significant reflex tachycardia.
• Dosing Protocol: Initial bolus of 20 mg IV over 2 minutes. If severe hypertension persists after 10 minutes, administer 40 mg IV. If still severe at 10 minutes, administer 80 mg IV. If still severe at 10 minutes, administer another 80 mg IV (maximum cumulative initial bolus dose: 220–300 mg). If control is not achieved, switch to hydralazine or nifedipine.
• Contraindications: Avoid in patients with asthma, severe reactive airway disease, decompensated heart failure, or severe sinus bradycardia (<60 bpm).

2. Intravenous Hydralazine

• Mechanism: Direct arteriolar smooth muscle vasodilator.
• Dosing Protocol: Initial bolus of 5 to 10 mg IV over 2 minutes. Recheck blood pressure in 20 minutes. If severe hypertension persists, administer 10 mg IV. If still severe after another 20 minutes, switch class (cumulative maximum dose: 20–30 mg).
• Midwifery Considerations: Hydralazine has a slower onset (10–20 minutes) and longer duration of action; rapid redosing can lead to profound maternal hypotension, reflex tachycardia, maternal headache, and fetal decelerations.

3. Oral Immediate-Release Nifedipine

• Mechanism: Dihydropyridine calcium channel blocker inhibiting transmembrane calcium influx in vascular smooth muscle.
• Dosing Protocol: 10 to 20 mg PO swallowed whole with water (never puncture, chew, or administer sublingually, which can cause erratic absorption and dangerous hypoperfusion). If severe hypertension persists at 20 minutes, administer 20 mg PO. If still severe at 40 minutes, administer another 20 mg PO (maximum cumulative initial dose: 50 mg).
• Clinical Advantage: Outstanding first-line choice when intravenous access has not yet been secured or in outpatient triage settings.

---

Seizure Prophylaxis: Magnesium Sulfate

Intravenous magnesium sulfate is the uncontested gold-standard pharmacologic agent for the prevention and treatment of eclamptic seizures. It is significantly superior to phenytoin, diazepam, and nimodipine. Magnesium acts centrally by blocking N-methyl-D-aspartate (NMDA) receptors, raising seizure thresholds, and producing cerebral vasodilation that alleviates preeclamptic cerebral vasospasm.

Clinical Indications

• All patients with preeclampsia with severe features, eclampsia, or HELLP syndrome during labor and for at least 24 hours postpartum.
• In patients with preeclampsia without severe features, routine administration is debated; shared decision-making and individualized assessment of clinical risk factors guide utilization.

Administration Protocols

• Loading Dose: 4 to 6 grams IV diluted in 100 mL of 5% Dextrose or 0.9% Normal Saline administered via an infusion pump over 20 to 30 minutes.
• Maintenance Infusion: 1 to 2 grams/hour continuous intravenous infusion.
• Intramuscular Alternative (Pritchard Regimen): Utilized when IV access is impossible or during transport: 4 g IV load plus 10 g IM (5 g in each buttock of 50% solution deep IM with 1% lidocaine), followed by 5 g IM every 4 hours into alternating buttocks.

Mandatory Clinical Monitoring & Toxicity Manifestations

Because magnesium is eliminated almost exclusively by the kidneys, maternal renal insufficiency can cause rapid accumulation and life-threatening toxicity.

Serum Magnesium Level (mg/dL)         Clinical Findings / Toxicity Stage
─────────────────────────────────────────────────────────────────────────
4.8 – 8.4 mg/dL (4–7 mEq/L)           Therapeutic Target Range
 9.0 – 12.0 mg/dL (7–10 mEq/L)        Loss of Deep Tendon (Patellar) Reflexes
12.0 – 15.0 mg/dL (10–12 mEq/L)       Respiratory Depression (<12 breaths/min)
15.0 – 17.0 mg/dL (12–15 mEq/L)       Altered Mental Status, Somnolence, Slurred Speech
 >20.0 mg/dL (>15 mEq/L)              Cardiac Arrest, Asystole, Complete Heart Block

• Serial Bedside Checks (Hourly):
  1. Patellar Reflexes: Must be present (+1 to +2). Loss of reflexes is the earliest clinical herald of impending toxicity.
  2. Respiratory Rate: Must be ≥12 breaths/minute. Count for a full 60 seconds.
  3. Urine Output: Must be ≥30 mL/hour (or ≥100 mL every 4 hours). If urine output drops below 30 mL/hr, serum magnesium levels will rise rapidly; reduce maintenance rate, obtain stat serum level, and monitor closely.
  4. Continuous Pulse Oximetry: Maintain SpO2 ≥95%.

Reversal of Magnesium Toxicity

If clinical signs of magnesium toxicity develop (loss of DTRs with bradypnea, severe somnolence, or cardiac compromise):

1. Immediately discontinue the magnesium sulfate infusion.
2. Call for emergency assistance and administer supplemental oxygen (10 L/min via non-rebreather mask).
3. Administer the direct antagonist: Calcium gluconate 1 gram IV (10 mL of a 10% solution) infused slowly over 3 to 5 minutes.
4. Support airway, breathing, and circulation; prepare for endotracheal intubation if respiratory arrest ensues.

---

Managing an Eclamptic Seizure at the Bedside

Eclampsia is a new-onset generalized tonic-clonic seizure in a patient with preeclampsia that is not attributable to another cause. It is the emergency that magnesium prophylaxis exists to prevent, and the midwife must be able to run the response.

Timing. Roughly one third of eclamptic seizures occur postpartum, most within the first 48 hours, and late postpartum eclampsia can occur up to 4 weeks after birth. Up to 20–38% of eclamptic seizures occur with no preceding classic warning signs, so the absence of headache or visual change never excludes the diagnosis.

Immediate Sequence

1. Call for help and activate the obstetric emergency response; note the time the seizure began.
2. Protect the patient, do not restrain her. Lower the bed, pad side rails, remove hard objects. Never force an airway, bite block, or tongue depressor into the mouth.
3. Position left lateral to reduce aspiration risk and relieve aortocaval compression.
4. Airway and oxygen: suction oral secretions after the tonic-clonic activity stops; apply oxygen 8–10 L/min by non-rebreather mask. Most seizures are self-limited at 60–90 seconds.
5. Magnesium sulfate is both the treatment and the ongoing prophylaxis: 4–6 g IV load over 15–20 minutes, then 2 g/hour. If a seizure recurs while on magnesium, give an additional 2 g IV bolus over 3–5 minutes.
6. Refractory seizures (a third seizure, or status) require a benzodiazepine (lorazepam 2–4 mg IV) or levetiracetam, anesthesia support for possible intubation, and neuroimaging to exclude intracranial hemorrhage or posterior reversible encephalopathy syndrome (PRES).
7. Control severe-range blood pressure with IV labetalol, IV hydralazine, or oral immediate-release nifedipine once the seizure has ended.

[!CAUTION] Do not rush to cesarean during or immediately after the seizure. Maternal hypoxia and hypercarbia during the convulsion routinely produce prolonged fetal bradycardia, late decelerations, and reduced variability that resolve over 3 to 10 minutes once the mother is oxygenated and stabilized. Stabilize the mother first — maternal resuscitation is fetal resuscitation. Operating on an unstable, seizing patient increases maternal risk without improving neonatal outcome.

After Stabilization

• Reassess maternal vital signs, neurologic status, and reflexes; draw a full preeclampsia panel including CBC, LDH, transaminases, creatinine, and coagulation studies.
• Delivery is indicated after maternal stabilization at any gestational age. Vaginal birth is preferred when the cervix is favorable and the fetal status allows.
• Continue magnesium sulfate for at least 24 hours after the last seizure or after birth, whichever is later.
• Investigate alternative causes if the seizure is atypical, focal, or occurs without hypertension: intracranial hemorrhage, cerebral venous thrombosis, hypoglycemia, hyponatremia, epilepsy, or drug toxicity.